TY - JOUR
T1 - Economic burden following allogeneic hematopoietic stem cell transplant in patients with diffuse large B-cell lymphoma
AU - Maziarz, Richard T.
AU - Hao, Yanni
AU - Guerin, Annie
AU - Gauthier, Genevieve
AU - Gauthier-Loiselle, Marjolaine
AU - Thomas, Simu K.
AU - Eldjerou, Lamis
N1 - Funding Information:
Financial support for this study was provided by Novartis Pharmaceuticals Corporation. The authors thank Cinzia Metallo, PhD, an employee of Analysis Group Inc., for editorial assistance, funded by Novartis Pharmaceuticals Corporation.
Funding Information:
This work was funded by Novartis Pharmaceuticals Corporation. Richard T. Maziarz is an employee of Oregon Health & Science University who provided and received payment for consultant services to Novartis Pharmaceuticals Corporation. This potential conflict of interest has been reviewed and managed by OHSU.
Funding Information:
This work was funded by Novartis Pharmaceuticals Corporation. Richard T. Maziarz is an employee of Oregon Health & Science University who provided and received payment for consultant services to Novartis Pharmaceuticals Corporation. This potential conflict of interest has been reviewed and managed by OHSU. Yanni Hao, Simu K Thomas, and Lamis Eldjerou are employees of Novartis Pharmaceuticals Corporation, which provided funding for this research. Annie Guerin, Genevieve Gauthier, and Marjolaine Gauthier-Loiselle are employees of Analysis Group Inc., which received consultancy fees from Novartis Pharmaceuticals Corporation for this research. Financial support for this study was provided by Novartis Pharmaceuticals Corporation. The authors thank Cinzia Metallo, PhD, an employee of Analysis Group Inc., for editorial assistance, funded by Novartis Pharmaceuticals Corporation.
Publisher Copyright:
© 2017 Informa UK Limited, trading as Taylor & Francis Group.
Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2018/5/4
Y1 - 2018/5/4
N2 - This study describes short-term and long-term healthcare resource utilization (HRU) and costs following an allogeneic hematopoietic stem cell transplant (HSCT) in adult patients with diffuse large B-cell lymphoma (DLBCL) in a real-world setting. Among 101 patients with DLBCL receiving an allogeneic HSCT, HRU and direct healthcare costs for up to three years after the allogeneic HSCT are described. HRU and costs were substantial, with the most intensive HRU and highest healthcare costs observed during the first year after HSCT (38 inpatient days; 68 days with office visits and average healthcare costs of $455,741). Although HRU and costs decreased over time, they remained high even in the third year after HSCT (four inpatient days; 27 days with office visits and average healthcare costs of $72,957). Overall, this study showed that the economic burden following an allogeneic HSCT in DLBCL patients is significant.
AB - This study describes short-term and long-term healthcare resource utilization (HRU) and costs following an allogeneic hematopoietic stem cell transplant (HSCT) in adult patients with diffuse large B-cell lymphoma (DLBCL) in a real-world setting. Among 101 patients with DLBCL receiving an allogeneic HSCT, HRU and direct healthcare costs for up to three years after the allogeneic HSCT are described. HRU and costs were substantial, with the most intensive HRU and highest healthcare costs observed during the first year after HSCT (38 inpatient days; 68 days with office visits and average healthcare costs of $455,741). Although HRU and costs decreased over time, they remained high even in the third year after HSCT (four inpatient days; 27 days with office visits and average healthcare costs of $72,957). Overall, this study showed that the economic burden following an allogeneic HSCT in DLBCL patients is significant.
KW - Diffuse large B-cell lymphoma
KW - allogeneic hematopoietic stem cell transplant
KW - economic burden
KW - healthcare costs
KW - healthcare resource utilization
UR - http://www.scopus.com/inward/record.url?scp=85029724172&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85029724172&partnerID=8YFLogxK
U2 - 10.1080/10428194.2017.1375100
DO - 10.1080/10428194.2017.1375100
M3 - Article
C2 - 28933643
AN - SCOPUS:85029724172
SN - 1042-8194
VL - 59
SP - 1133
EP - 1142
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 5
ER -